Advanced searches left 3/3

Metastatic Prostate Cancer - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 27 April 2022

* If you want to update the article please login/register

Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Background: This review aims to determine a radiolabeled small molecule inhibitor of prostate-specific prostate cancer, with the exception of histological marker of prostate cancer tumor aggressiveness and metastatic potential. [18F] DCFPyL PET/CT, a well-known histological marker of prostate cancer tumor proliferation and metastatic prostate cancer spotting. We recommend that we investigate the ability of DCFPyL PET to detect metastatic prostate cancer by visual qualitative and quantitative SUV testing. Correlation will be sent to places of suspected bony metastatic disease detected by ultra-sensitive but less specific [18F] Sodium Fluoride -PET/CT imaging and all sites of suspected disease by [18F] Fluorodeoxyglucose for prostate cancer. On at least one clinically demonstrated imaging modality, the confirmation of prostate cancer with distinct metastatic disease has been confirmed. Two Cohort studies are combined: Prostate Specific Antigen (PSA): The last PSA value must be greater than or less than 0. 5 ng/mL value obtained on at least two occasions within a year Cohort 2: Patients must be able to or less than 0. 5 ng/mL value of the last PSA Maximum; Prostate Specific Antigen; More than 0. 5 ng/mL value on at least two occasions within 1 year The last PSA must be higher than The DCFPyL PET/CT findings of metastatic disease detection can be assessed as positive, equivocal, or negative by visual qualitative evaluation as positive, equivocal, or negative.

Source link: https://clinicaltrials.gov/ct2/show/NCT03173924


Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

The hypothesis that is being tested is that administering two vaccines with PD-1 blockade will increase the frequency and extent of tumor-directed CD8+ T cells, raising the risk of patients experiencing objective anti-tumor therapy as determined by PSA declines and/or objective radiographic responses, which would increase the risk and severity of tumor-directed CD8+ T cells.

Source link: https://clinicaltrials.gov/ct2/show/NCT04090528


A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

In conjunction with AAP for the care of patients with metastatic castration resistant prostate cancer, this research will determine the efficacy and safety of niraparib. Niraparib is an orally available, highly selective polymerases inhibitor with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid -repair polymerases. In participants with metastatic prostate cancer, DNA-repair anomalies have been detected in around 15% to 20% of tumors. Participants will be tested for homologous recombination repair gene mutation status during the prescreening process and then assigned to one of the two groups based on their biomarker status.

Source link: https://clinicaltrials.gov/ct2/show/NCT03748641


Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate With Prednisone and Androgen Deprivation Therapy After Treatment With Docetaxel and Androgen Deprivation Therapy

I. Efficacy of apalutamide in combination with abiraterone acetate + prednisone following docetaxel therapy in men with a high risk metastatic castration sensitive disease. Following docetaxel therapy with continuing androgen deprivation therapy, apalutamide's safety and tolerability are combined with abiraterone acetate + prednisone. Prostate cancer tumor DNA has mutated with time. OUTLINE: Patients are given apalutamide orally every day, abiraterone acetate PO QD, and prednisone PO QD. Patients are also receiving androgen deprivation therapy as per the highest level of care.

Source link: https://clinicaltrials.gov/ct2/show/NCT04267887


An Exploratory Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide (XTANDI) Androgen Receptor (AR)-Directed Therapy in Hormono-Sensitive Patients With Metastatic Prostate Cancer (Hormono-sensitive Patients)

Metastatic prostate cancer patients who are eligible for 1st-line hormonal therapy will be treated with Enzalutamide. Subjects will be given 1dd 160 mg Enzalutamide orally daily until progressive disease is present. CTC counts and characteristics will be measured at baseline and during Enzalutamide therapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT02815033


Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Despite androgen deprivation therapy, the study was conducted in a multinational Phase 3, double-blind, placebo-controlled efficacy, and safety study of oral enzalutamide in asymptomatic or mildly symptomatic participants of progressive metastatic prostate cancer with disease progression despite androgen deprivation therapy. Participants in the PK cohort were expected to be hospitalized from Day 1 until the randomization date, and at least the end of all of the assessments planned on Day 3. All participants in the PK cohort underwent blood testing for the PK analysis.

Source link: https://clinicaltrials.gov/ct2/show/NCT02294461


STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial

STAMPEDE, a multi-arm controlled trial recruiting scheme in the United Kingdom and Switzerland, is a multi-arm multi-stage randomised controlled trial recruiting process. Even if the enforcement arm did not proceed to the final stage, patient results from all arms and all stages are, however, included in the final evaluations of the primary outcome measure. Even if the investigation arm did not progress to the final stage, patient data from all arms and all stages is included in the final analyses of the primary outcome measure. STAMPEDE's new research arms have been added to the trial over time: abiraterone, a hormone synthesis inhibitor, and prostate radiotherapy for patients with newly diagnosed metastatic disease; and metformin, an anti-diabetic drug and transdermal oestradiol, will be used as an alternative form of ADT. Specifically, primary ADT for the first time, Objectives: Primary To evaluate the safety and effectiveness of novel therapeutic treatments against the current standard-of-care for men with high-risk locally advanced or metastatic prostate cancer with high-risk prostate cancer starting long-term ADT. Patients in the hospital: STAMPEDE has recruited both men with high-risk locally advanced prostate cancer and men with metastatic prostate cancer, both of whom must begin long-term ADT for the first time. All patients are follow-up life long as part of STAMPEDE, and several translational sub-studies are ongoing. Multiple translational sub-studies are currently available: saliva collection for germline DNA analysis, sequential circulating tumour DNA analysis, and FFPE tumor block retrieval for DNA and RNA analysis.

Source link: https://clinicaltrials.gov/ct2/show/NCT00268476

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions